HC Wainwright Reaffirms “Buy” Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $3.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 203.03% from the company’s current price.

Barinthus Biotherapeutics Stock Down 2.0 %

Shares of NASDAQ:BRNS opened at $0.99 on Friday. Barinthus Biotherapeutics has a 52-week low of $0.80 and a 52-week high of $4.16. The company has a 50 day moving average of $1.01 and a two-hundred day moving average of $1.12. The company has a market capitalization of $39.83 million, a price-to-earnings ratio of -0.66 and a beta of -0.80.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $14.97 million for the quarter. On average, equities analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. bought a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th biggest position. Gilead Sciences Inc. owned 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.